Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer

Creative Commons License

ERTÜRK Z., BÜBER E., Ozen H., ÇELİKBIÇAK Ö., SALİH B., Acan N. L.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.16, no.3, pp.70-76, 2017 (ESCI, TRDizin) identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.4274/uob.905
  • Journal Name: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.70-76
  • Keywords: Mycobacterium brumae, non-muscle invasive bladder cancer, high performance liquid chromatography, matrix-assisted laser desorption/ionization-mass spectrometry, tumour necrosis factor-alpha, BACILLUS-CALMETTE-GUERIN, INVASIVE UROTHELIAL CARCINOMA, CELL-WALL, BCG THERAPY, BOVIS BCG, GUIDELINES, MANAGEMENT, TUMOR
  • Open Archive Collection: AVESIS Open Access Collection
  • Hacettepe University Affiliated: Yes

Abstract

Objective: Immunotherapy with intravesical Bacillus Calmette-Guerin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain.